

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandria, Virginia 22313-1450 www.asylo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/955,373	10/21/1997	SOREN MOURITSEN	BNIT0003-US	7254
98994 98991 99916/2011 BN Immuno Therapeutics, Inc. 2425 Garcia Avenue Mountain View, CA 94043-1106			EXAMINER	
			SCHWADRON, RONALD B	
			ART UNIT	PAPER NUMBER
			1644	•
			NOTIFICATION DATE	DELIVERY MODE
			09/16/2011	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail $\,$ address(es):

david.hoffman@bn-it.com

Notice of Non-Compliant Amendment (37 CFR 1.121)

Application No.	Applicant(s)
08/955,373	MOURITSEN ET AL.
Examiner	Art Unit
Ron Schwadron, Ph.D.	1644

The amendment document filed on 17 June 2011 is considered non-compliant because it has failed to meet the

requirements of 37 CFR 1.121 or 1.4. In order for the amendm item(s) is required.	
THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE AMEN 1. Amendments to the specification: A. Amended paragraph(s) do not include mark B. New paragraph(s) should not be underlined. C. Other	ings.
2. Abstract: A. Not presented on a separate sheet. 37 CFR B. Other	1.72.
"Annotated Sheet" as required by 37 CFR 1 B. The practice of submitting proposed drawing	he top margin as "Replacement Sheet," "New Sheet," or .121(d). g correction has been eliminated. Replacement drawings s, in compliance with 37 CFR 1.84 are required.
 C. Each claim has not been provided with the p of each claim cannot be identified. Note: the number by using one of the following status 	kt of all pending claims (including withdrawn claims) oroper status identifier, and as such, the individual status le status of every claim must be indicated after its claim identifiers: (Original), (Currently amended), (Canceled), j. (Withdrawn) and (Withdrawn-currently amended),
5. Other (e.g., the amendment is unsigned or not sign	ned in accordance with 37 CFR 1.4):
For further explanation of the amendment format required by	37 CFR 1.121, see MPEP § 714.
TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:	
 Applicant is given no new time period if the non-complian filed after allowance. If applicant wishes to resubmit the nentire corrected amendment must be resubmitted. 	
(including a submission for a request for continued examin amendment filed within a suspension period under 37 CFI	following: a preliminary amendment, a non-final amendment nation (RCE) under 37 CFR 1.114), a supplemental R 1.103(a) or (c), and an amendment filed in response to a the correction required is only the corrected section of the
Extensions of time are available under 37 CFR 1.136 amendment or an amendment filed in response to a Qu	
filed in response to a Quayle action; or	nt amendment is a non-final amendment or an amendment immediately immediately in the supplemental in the s
Ron Schwadron, Ph.D. Primary Examiner, Art Unit 1644	/Ron Schwadron/

Primary Examiner, Art Unit 1644

⁻⁻ The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Continuation Sheet (PTOL-324) Application No. 08/955,373

Continuation of 3(c) Other: New drawings in response to the Office action of 7/14/99, paragraph 6 have never been filed. Figure 1 is unreadable in its current form.

Continuation of 4(e) Other: In claim 88, line 5, the comma after "epitopes" is underlined wherein the comma had already been previously added..